This study is for children and young adults (up to 25 years old) with certain blood cancers like leukemia or myelodysplasia. It's testing a new way to prepare for a blood stem cell transplant. You would receive a stem cell transplant where the donor cells are specially treated using a device called CliniMACS. This device removes specific immune cells (alpha/beta T cells and B cells) from the donor's blood. The goal is to see how well this method prevents a common transplant complication called graft-versus-host disease (aGVHD) and helps the new cells settle in (engraftment). The study aims to enroll 40 participants, but its current recruitment status is unclear.

Study design

This is a single-arm study, meaning all participants receive the same treatment. It is a pilot study, and the phase is not specified. It plans to enroll 40 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints, including the incidence and extent of aGVHD and engraftment, will be measured at 1 year after the transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.